Farther Finance Advisors LLC Buys 4,091 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 176.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,404 shares of the company’s stock after acquiring an additional 4,091 shares during the period. Farther Finance Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $42,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 14.5% in the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after buying an additional 3,555,357 shares in the last quarter. Baillie Gifford & Co. raised its stake in Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after purchasing an additional 2,522,132 shares in the last quarter. Kinnevik AB publ lifted its position in Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after purchasing an additional 1,500,000 shares during the period. Lingotto Investment Management LLP increased its holdings in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after buying an additional 1,500,000 shares during the period. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at approximately $8,250,000. Institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.25.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 2.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 183,129 shares of company stock worth $1,214,974 over the last ninety days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Trading Down 5.6 %

RXRX opened at $6.91 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.89 and a fifty-two week high of $15.74. The company’s 50 day moving average price is $6.64 and its two-hundred day moving average price is $7.62. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.78 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.43) EPS. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.